Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) Director George Jenkins sold 12,371 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $151.28, for a total transaction of $1,871,484.88. Following the completion of the transaction, the director owned 175,245 shares of the company’s stock, valued at approximately $26,511,063.60. The trade was a 6.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Palvella Therapeutics Stock Down 0.3%
Shares of Palvella Therapeutics stock traded down $0.47 during trading on Tuesday, hitting $151.22. The stock had a trading volume of 215,632 shares, compared to its average volume of 186,628. Palvella Therapeutics, Inc. has a 1 year low of $54.28 and a 1 year high of $161.38. The stock has a 50 day simple moving average of $149.13 and a 200 day simple moving average of $132.62. The company has a market capitalization of $2.18 billion, a PE ratio of -31.31 and a beta of -0.25.
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.35). As a group, equities analysts expect that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.
Institutional Trading of Palvella Therapeutics
Analysts Set New Price Targets
PVLA has been the subject of a number of research analyst reports. Truist Financial set a $207.00 target price on Palvella Therapeutics in a report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a report on Wednesday, August 5th. HC Wainwright reissued a “buy” rating and set a $270.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, July 22nd. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $209.14.
Read Our Latest Research Report on PVLA
About Palvella Therapeutics
Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare genetic and dermatologic diseases. The company uses its proprietary QTORIN platform to formulate and deliver medicines locally to affected tissues, with the goal of improving treatment effectiveness while limiting systemic exposure.
Palvella’s lead program is QTORIN 3.9% rapamycin, an investigational topical gel being developed for microcystic lymphatic malformations, rare lesions caused by abnormalities in the lymphatic system.
Featured Articles
- Five stocks we like better than Palvella Therapeutics
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
